ERBB2 and breast carcinoma: We generated HER2-positive breast cancer cell models with resistance to trastuzumab and pertuzumab via prolonged exposure to both antibodies in a panel of four HER2-positive BCCLs and characterized them in terms of their proliferative and clonogenic potential.